Market research
EDSA Edesa Biotech Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 43M
- P/E ratio
- Not available
- Analyst target
- 16.3333
- Dividend yield
- Not available
- Beta
- 1.08
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA27966L3065
- Market cap
- 43M
- P/E ratio
- Not available
- Analyst target
- 16.3333
- Dividend yield
- Not available
- Beta
- 1.08
About
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EDSA discussion.
5 years, 4 months ago
Edesa Biotech, Inc is currently in a long term downtrend where the price is trading 10.2% below its 200 day moving average.
From a valuation standpoint, the stock is 82.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 236.5.
Edesa Biotech, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 141.0% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 281.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Edesa Biotech, Inc gets an overall score of 1/5.